|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication January 9, 2008.
Revised March 19, 2008.
Accepted for publication March 24, 2008.
4
2 nicotinic acetylcholine receptors
Sazetidine-A has been recently proposed to be a "silent desensitizer" of
4
2 nicotinic acetylcholine receptors (nAChRs), implying that it desensitizes
4
2 nAChRs without first activating them. This unusual pharmacological property of sazetidine-A makes it, potentially, an excellent research tool to distinguish between the role of activation and desensitization of
4
2 nAChRs in mediating the CNS effects of nicotine itself, as well as those of new nicotinic drugs. Surprisingly, we found that sazetidine-A potently and efficaciously stimulates nAChR-mediated dopamine release from rat striatal slices, which is mediated by
4
2* and
6
2* nAChRs. The agonist effects on native striatal nAChRs prompted us to re-examine the effects of sazetidine-A on recombinant
4
2 nAChRs in more detail. We expressed the two alternative stoichiometries of
4
2 nAChR in Xenopus oocytes and investigated the agonist properties of sazetidine-A on both
4(2)
2(3) and
4(3)
2(2) nAChRs. We found that sazetidine-A potently activated both stoichiometries of
4
2 nAChR: it was a full agonist on
4(2)
2(3) nAChRs, whereas it had an efficacy of only 6% on
4(3)
2(2) nAChRs. In contrast to what has been published before, we therefore conclude that sazetidine-A is an agonist of native and recombinant
4
2 nAChRs while showing differential efficacy on
4
2 nAChRs subtypes.
Key words:
Nicotinic cholinergic, Func. analysis receptor/ion channel mutants, Receptor binding studies